| Prognostic value of melanoma-associated antigen A9 in renal cell carcinoma. | |
| | |
MedLine Citation:
|
PMID: 23140095 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
Abstract Objective. The aim of this study was to evaluate the prognostic relevance of melanoma-associated antigen (MAGE) A9 in renal cell carcinoma (RCC). Material and methods. Immunohistochemical staining for MAGE A9 was evaluated in a tissue microarray containing 587 RCC tumour tissue samples. Nuclear MAGE A9 expression was reviewed using a semiquantitative score. Follow-up has been surveyed since 1990 in a prospectively conducted tumour database. The effect of MAGE A9 expression on cancer-specific survival (CSS) was assessed by univariate and multivariate Cox regression analyses. Subgroup analyses were performed for non-metastatic and metastatic disease. Results.Median age in all patients was 63.2 years, 354 patients were male and 233 female, and 108 patients had metastatic disease. Median follow-up was 5.6 years for all patients and 9.0 years for patients still alive (range 0-19.9 years). High nuclear MAGE A9 expression was present in 326 tumour specimens (55.5%). In multivariate analyses high nuclear MAGE A9 expression was associated with poor CSS (p = 0.0027). Furthermore, tumour stage, lymph-node and distant metastasis, Fuhrman grade G3/4, Karnofsky index < 80% and male gender were associated with poor CSS. In subgroup analyses, results were concordant for patients with non-metastatic disease. In patients with metastatic disease, only Karnofsky index > 80% was a significant predictor for CSS; MAGE A9 expression could not be shown to be associated with CSS (p = 0.161). Conclusions.High nuclear MAGE A9 expression is independently associated with poor CSS in patients with non-metastatic RCC. The assessment of MAGE A9 expression can provide additional prognostic information and should be used in decision-making regarding adjuvant therapy in patients with non-metastatic disease. |
| | |
Authors:
|
Gencay Hatiboglu; Maria Pritsch; Stephan Macher-Goeppinger; Margot Zöller; Johannes Huber; Axel Haferkamp; Sascha Pahernik; Nina Wagener; Markus Hohenfellner |
Related Documents
:
|
15749665 - The impact of the combination of baseline risk group and cytogenetic response on the su... 8991115 - Autologous bone marrow transplantation in chronic lymphocytic leukemia (cll). 23026285 - Palliative therapy for patients with unresectable esophageal carcinoma. 23301725 - Favorable outcome with doxorubicin-based chemotherapy and radiotherapy for adult patien... 22645605 - Prevention of peritoneal metastases from colon cancer in high-risk patients: preliminar... 22954785 - Prognostic significance of rising serum ca-125 levels within the normal range in patien... |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2012-11-12 |
Journal Detail:
|
Title: Scandinavian journal of urology and nephrology Volume: - ISSN: 1651-2065 ISO Abbreviation: Scand. J. Urol. Nephrol. Publication Date: 2012 Nov |
Date Detail:
|
Created Date: 2012-11-12 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0114501 Medline TA: Scand J Urol Nephrol Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
Department of Urology. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Breast Self-Examination and breast cancer awareness in women in developing countries: a survey of wo...
Next Document: Leaf endophyte load influences fungal garden development in leaf-cutting ants.